← All Hutchmed (china) LTD filings

Hutchmed (china) LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
HCM
Hutchmed (china) LTD
20-F: HUTCHMED Boosts Net Income with Strategic Divestment Amidst R&D Shift
HUTCHMED (China) Limited reported a significant increase in net income to $456.9 million in 2025, primarily driven by a $415.8 million net gain from the partial divestment of Shanghai Hutchison Pharmaceuticals, despite a decline in consolidated revenue.
NASDAQ
HCM
Hutchmed (china) LTD
20-F: HUTCHMED (China) Limited Files 20-F Annual Report for Fiscal Year 2024
HUTCHMED (China) Limited releases its annual report on Form 20-F, detailing the company's performance and financial standing for the fiscal year ended December 31, 2024.
NASDAQ
HCM
Hutchmed (china) LTD
20-F: HUTCHMED Details Ordinary Share Structure in 20-F Filing
HUTCHMED's 20-F filing provides a detailed overview of the company's ordinary shares, including dividend rights, voting rights, transfer procedures, and liquidation preferences, as well as differences in corporate law between the Cayman Islands and the United States.